Inventor
REFF MITCHELL E
US20 patents
⚠️ This page may combine multiple inventors who share the name “REFF MITCHELL E”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IDEC PHARMA CORP
10 patentsUS6682734B1Jan 27, 2004
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
IDEC PHARMA CORP176 citations99
US6399061B1Jun 4, 2002
Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma
IDEC PHARMA CORP254 citations99
US6159730ADec 12, 2000
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
IDEC PHARMA CORP123 citations99
US5776456AJul 7, 1998
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
IDEC PHARMA CORP527 citations99
US5736137AApr 7, 1998
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
IDEC PHARMA CORP1,577 citations99
US6011138AJan 4, 2000
Gamma-1 anti-human CD23 monoclonal antibodies
IDEC PHARMA CORP93 citations97
US5733779AMar 31, 1998
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
IDEC PHARMA CORP85 citations96
US5648267AJul 15, 1997
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
IDEC PHARMA CORP82 citations96
US5830698ANov 3, 1998
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
IDEC PHARMA CORP76 citations94
US6017733AJan 25, 2000
Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
IDEC PHARMA CORP24 citations92
BIOGEN IDEC INC
9 patentsUS7422739B2Sep 9, 2008
Anti-CD20 antibodies
BIOGEN IDEC INC166 citations99
US7381560B2Jun 3, 2008
Expression and use of anti-CD20 antibodies
BIOGEN IDEC INC45 citations96
US7033589B1Apr 25, 2006
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
BIOGEN IDEC INC53 citations95
US7744877B2Jun 29, 2010
Expression and use of anti-CD20 Antibodies
BIOGEN IDEC INC38 citations92
US6893636B2May 17, 2005
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
BIOGEN IDEC INC13 citations92
US7223392B2May 29, 2007
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
BIOGEN IDEC INC10 citations83
US7438906B2Oct 21, 2008
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
BIOGEN IDEC INC3 citations62
US7332163B2Feb 19, 2008
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
BIOGEN IDEC INC3 citations62
US7695940B2Apr 13, 2010
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
BIOGEN IDEC INC0 citations51